Ivonescimab is the first therapy to achieve statistically significant positive results in a Phase III trial compared with ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

CANCER remains a critical health challenge in Malaysia. This rising trend highlights the urgent need for effective ...

Targeted chemotherapy and genomics testing have made treatment outcomes much better. There are drugs with fewer side effects ...

Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT ...

Pfizer Inc. today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC) Bacillus ...

Ivonescimab monotherapy demonstrated a statistically significant improvement in the trial’s primary endpoint, progression-free survival (PFS) by independent radiologic review committee (IRRC), ...

Q1 2025 Earnings Call Transcript April 25, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.46, expectations ...

Kelly Shi from Jefferies sets a price target of $44 for NASDAQ:SMMT, indicating a potential increase of approximately 71.84%.

Abbott has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Volttm PFA System ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

People who are immunocompromised cannot get immunized against measles because the vaccine contains a live attenuated virus, a ...